Abstract
Intradialytic hypotension (IDH) is associated with high mortality. Peripheral vascular resistance and circulating blood volume are important factors in IDH; however, the effects of hemodialysis (HD) on vascular resistance in IDH remain unclear. We herein performed a retrospective observational cohort study to investigate changes in and factors related to vascular resistance during HD. A total of 101 HD patients were divided into two groups (Decreased blood pressure (BP) during HD group: N = 19, Nondecreased BP group: N = 82), and cardiac output was measured with electrical velocimetry (AESCLON) for 3 h. The systemic vascular resistance index (SVRI) was significantly decreased in the Decreased BP group, while the cardiac index was similar in both groups. A multivariate regression analysis identified hypocholesterolemia as a predictor of reduced vascular resistance reactivity during HD. Furthermore, a correlation was found between changes in the SVRI and cholesterol levels in patients with a higher Geriatric Nutritional Risk Index (GNRI) but not in those with a lower GNRI. The present results suggest that hypocholesterolemia contributes to reducing systematic vascular resistance reactivity during HD, which is an important predictor of a reduction in BP during HD. The relationship between hypocholesterolemia and vascular resistance may involve mechanisms other than malnutrition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, et al. EBPG guideline on hemodynamic instability. Nephrol Dial Transpl. 2007;22:ii22–44.
Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–20.
Puskar D, Pasini J, Savic I, Bedalov G, Sonicki Z. Survival of primary arteriovenous fistula in 463 patients on chronic hemodialysis. Croat Med J. 2002;43:306–31.
Nette RW, van den Dorpel MA, Krepel HP, le EHY, van den Meiracker AH, Poldermans D, et al. Hypotension during hemodialysis results from an impairment of arteriolar tone and left ventricular function. Clin Nephrol. 2005;63:276–83.
Straver B, Roggekamp MC, de Vries PM, ter Wee PM. Systemic vascular resistance in intradialytic hypotension determined by means of impedance cardiography. Blood Purif. 1998;16:281–9.
Kubo K, Sanaka T, Suzuki T, Muto H, Sugino N, Kimata S. Cardiovascular function of patients undertaking longterm hemodialysis, Part II—clinical evaluation of hemodynamic changes during hemodialysis. Jpn Soc Dialysis Ther. 1981;14:1–6.
Yoshihara F, Kishida M, Ogawa K, Nishigaki T, Nakasaki H, Isgizuka A, et al. Stroke volume variation is an independent predictor for decreased blood pressure during hemodialysis. Ther Apher Dial. 2017;21:166–72.
Murasawa T, Hanyuda Y, Suzuki O, Ueda Y, Hara F. Evaluation of cardiac function during hemodialysis in diabetic nephropathy as reflected in double product, Stroke work index and systemic vascular resistance. Jpn J Artif Organs. 1988;17:94–7.
Frank M, Ulrich G, Jeroen P, George B, Karel M. Energy transfer is the single most important factor for the difference in vascular response between isolated ultrafiltration and hemodialysis. J Am Soc Nephrol. 2000;11:1512–7.
Toshiki F, Hideaki H, Katsuyuki N, Yuji Y. Prognostic expectation of hemodialysis patients using Geriatric Nutritional Risk Index(GNRI): comparison with single application of body mass index (BMI) or serum albumin. Tosekikaishi. 2014;47:75–84.
Burton JO, Jefferies HJ, Selby NM, McIntyre CW. Hemodialysis-induced cardiac injury: determinants and associated outcomes. Clin J Am Soc Nephrol. 2009;4:914–20.
Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887–93.
Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, et al. Mortality risk factors in patients treated by chronic hemodialysis. report of the Diaphane collaborative study. Nephron. 1982;31:103–10.
Sageman S, Riffenburgh R, Spiess B. Equivalence of bioimpedance and Thermodilution in measuring cardiac index after cardiac surgery. J Cardiothorac Vasc Anesth. 2002;6:8–14.
Schmidt C, Theilmeier G, Van Aken H, Korsmeier P, P. Wirtz S, Berendes E, et al. Comparison of electrical velocimetry and transesophageal Doppler echocardiography for measuring stroke volume and cardiac output. Br J Anaesth. 2005;95:603–10.
Zoremba N, Bickenbach J, Krauss B, Rossaint R, Kuhlen R, Schalte G. Comparison of electrical velocimetry and thermodilution techniques for the measurement of cardiac output. Acta Anaesthesiol Scand. 2007;51:1314–9.
Xiong J, Wang M, Zhang Y, Nie L, He T, Wang Y, et al. Association of Geriatric Nutritional Risk Index with mortality in hemodialysis patients: a meta-analysis of cohort studies. Kidney Blood Press Res. 2018;43:1878–89.
Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451–9.
Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int. 1993;44:1086–90.
Ettema EM, Kuipers J, Groen H, Kema IP, Westerhuis R, Jong PE, et al. Vasopressin release is enhanced by the Hemocontrol biofeedback system and could contribute to better haemodynamic stability during haemodialysis. Nephrol Dial Transpl. 2012;27:3263–70.
El-Shafey EM, El-Nagar GF, Selim MF, El-Sorogy HA, Sabry AA. Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis? Clin Exp Nephrol. 2008;12:370–5.
Raj DS, Vincent B, Simpson K, Sato E, Jones KL, Welbourne TC, et al. Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin. Kidney Int. 2002;61:697–704.
Teng J, Tian J, Lv WL, Zhang XY, Zou JZ, Fang Y, et al. Inappropriately elevated endothelin-1 plays a role in the pathogenesis of intradialytic hypertension. Hemodial Int. 2015;19:279–86.
Nakamura T, Ushiyama C, Osada S, Inoue T, Shimada N, Koide H. Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. J Diabetes Complications. 2003;17:349–54.
Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241:433–42.
Ohwaki T, Sakai H, Hirata Y. Partial characterization of endothelin-converting enzyme activity in human serum. Atherosclerosis. 1994;108:175–81.
Merkel LA, Bilder GE. Modulation of vascular reactivity by vasoactive peptides in aortic rings from hypercholesterolemic rabbits. Eur J Pharm. 1992;222:175–9.
Mathew V, Cannan CR, Miller VM, Barber DA, Hasdai D, Schwartz RS, et al. Enhanced endothelin-mediated coronary vasoconstriction and attenuated basal nitric oxide activity in experimental hypercholesterolemia. Circulation. 1997;96:1930–6.
Romerio SC, Linder L, Flammer J, Haefeli WE. Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. Peptides. 2000;21:871–4.
Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharm Ther. 2014;143:87–110.
Samouilidou EC, Karpouza AP, Kostopoulos V, Bakirtzi T, Pantelias K, Petras D, et al. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis. Ren Fail. 2012;34:160–4.
Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213–8.
Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003;107:992–5.
Gutkin M, Levinson GE, King AS, Lasker N. Plasma renin activity in end-stage kidney disease. Circulation. 1969;40:563–74.
Craswell PW, Hird VM, Judd PA, Baillod RA, Varghese Z, Moorhead JF. Plasma renin activity and blood pressure in 89 patients receiving maintenance haemodialysis therapy. Br Med J. 1972;4:749–53.
Acknowledgements
We thank Yoko Saito and Chie Nishiguchi for their excellent assistance. This study was supported by a 2019 Novartis Research Grant.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Matsuo, M., Kojima, S., Arisato, T. et al. Hypocholesterolemia is a risk factor for reduced systemic vascular resistance reactivity during hemodialysis. Hypertens Res 44, 988–995 (2021). https://doi.org/10.1038/s41440-021-00640-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-021-00640-2
Keywords
This article is cited by
-
Effect of total cholesterol and statin therapy on mortality in ARDS patients: a secondary analysis of the SAILS and HARP-2 trials
Critical Care (2023)
-
Effect of low-density lipoprotein level and mortality in older incident statin-naïve hemodialysis patients
BMC Nephrology (2023)
-
Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis
Hypertension Research (2022)